WAYNE, PA — Teleflex Incorporated (NYSE: TFX) recently announced a new agreement with FundamentalVR. The agreement will provide Teleflex with a VR training platform to accelerate the effective use of the company’s UroLift® 2 System, an innovative technology for treatment of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. The VR training platform integrates tactile feedback and a digital representation of the UroLift® 2 System to provide urologists with a “hands-on” VR experience that can accelerate their learning.
By leveraging the capabilities of FundamentalVR’s Fundamental Surgery platform, Teleflex aims to increase access and standardization of clinical training of the UroLift® 2 System in the United States and around the world, including Japan, where the UroLift® 2 System was recently approved for use. The customized solution from FundamentalVR will enable urologists globally to practice the procedure remotely in a virtual environment.
Teleflex showcased the Fundamental Surgery platform at the company’s UroLift® System booth at the 2022 American Urological Association (AUA) meeting in New Orleans. The platform is officially launching and becoming available in August 2022.
“We are delighted to offer our customers this leading VR platform for surgical and procedural education which offers advanced, realistic graphics to help demonstrate the ease of use of the UroLift® 2 System in a variety of prostate anatomies,” said Kevin Hardage, President and General Manager of Teleflex Interventional Urology. “FundamentalVR’s Fundamental Surgery platform is versatile and scalable, making them an ideal supplier to meet our customers’ needs for training for the UroLift® 2 System around the world.”
Chris Scattergood, co-founder at FundamentalVR said, “We are delighted that Teleflex, a market leader in urology, has chosen FundamentalVR as their partner for their future vision. Integrating Extended Reality education solutions can have a positive impact on surgeons and patients.”
Original post here